Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology VC (Venture Capital) Funds in Belgium in November 2024

Last updated: Nov 2024 A list of 50 VC (Venture Capital) funds that invest in Biotechnology startups based in Belgium. We rank investors based on the number of investments they made in Biotechnology companies from Belgium. We update this investor list every month.

Top 50 Biotechnology VC (Venture Capital) Funds in Belgium in November 2024

Investor	Biotechnology Belgium investments
PMV	15
S.R.I.W.	13
V-Bio Ventures	12
Qbic Fund	11
Gemma Frisius Fund	10
VIB	10
Meusinvest (Noshaq)	10
Vives Louvain Technology Fund	9
Gimv	8
Limburgse Reconversie Maatschappij	8
Capricorn Partners	7
Vesalius Biocapital Partners	6
Sambrinvest	5
Newton Biocapital	5
Boehringer Ingelheim Venture Fund	4
EQT Life Sciences	4
Omnes Capital	4
Baekeland Funds	4
KBC	4
Spinventure	3
BioGeneration Ventures	3
Fund+	3
Inventures SA	3
Droia Ventures	3
Qbic	3
Theodorus III	3
UCB Ventures	3
New Science Ventures	3
AdBio partners	3
Agri Investment Fund	2
Thuja Capital	2
GoBeyond	2
Vinnof	2
Novo Holdings	2
Pontifax	2
SFPI-FPIM	2
M Ventures	2
Ackermans & van Haaren	2
Quest for Growth	2
Forbion Capital Partners	2
Innovation Fund	2
Johnson & Johnson Innovation – JJDC	2
Sofinnova Partners	2
Fountain Healthcare Partners	2
Spreds	2
Nivelinvest	2
Capital-E	2
Merieux Developpement	2
European Investment Bank	1
Biotech Fund Flanders	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Do and dare company

Investment focus

Software, Biotechnology, Health Care
Series A, Seed, Series B
Belgium, United States, The Netherlands

Portfolio highlights

Accurat — Accurat provides real-word shopper insights to support retail decision making with unprecedented accuracy. Our proprietary technology, platform and algorithms understand behaviour in high detail.
Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the SociÃ©tÃ© RÃ©gionaledâ€™Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

Investment focus

Biotechnology, Health Care, Manufacturing
Funding Round, Series A, Series B
Belgium, United States, Spain

Portfolio highlights

Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.

Investment focus

Biotechnology, Software, Health Care
Seed, Funding Round, Series A
Belgium

Portfolio highlights

Weavely — Design forms in Figma - publish with Weavely. We turn your visual ideas into interactive, web-based forms.
Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series B, Series A
Belgium, France, United Kingdom

Portfolio highlights

DName-iT — DName-iT is a genetic analysis tool that offers DNA-based barcode labeling technology and a software platform that can ensure reliable, cost-effective NGS specimen identification.
Protealis — Sustainable plant proteins for Europe
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

Strategic research in on life sciences and biotechnology

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series A, Series B, Funding Round
Belgium, Brazil, Denmark

Portfolio highlights

Protealis — Sustainable plant proteins for Europe
Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Belgium, France, United States

Portfolio highlights

BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Private Equity
Belgium, United States, France

Portfolio highlights

Curana — Curana is a manufacturer of bike equipment and accessories.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Oxygen for growth - LRM

Investment focus

Information Technology, Software, Biotechnology
Funding Round, Series A, Seed
Belgium, United States, The Netherlands

Portfolio highlights

Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
MobieTrain — Unlock the potential of your customer-facing employees and create memorable customer experiences with MobieTrain's app.
Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Investment focus

Biotechnology, Health Care, Software
Funding Round, Series B, Series A
Belgium, United States, The Netherlands

Portfolio highlights

Thryve — Thryve’s SDK brings everything you need to access fragmented wearable, medical devices, and health data silos with a single integration. We unify your users’ data from smartwatches, blood glucose meters, and many other sources that unlock a continuous stream of harmonized health information for your care. We support popular data sources like AppleHealth, Google Fit, Huawei Health, Samsung Health, and many more.
Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
Electric Hydrogen — Electric Hydrogen designs and builds low-cost, high-efficiency green hydrogen systems to economically decarbonize industrial sectors like ammonia and steel

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
Belgium, Germany, The Netherlands

Portfolio highlights

CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Caresyntax — Caresyntax is the only enterprise-scale surgical data solution you need to make surgery smarter, safer, and more profitable.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Series A, Series B
Belgium, France, Spain

Portfolio highlights

cikisi — Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution.
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
Belgium, Japan, France

Portfolio highlights

AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Omnes, "Powering Entrepreneurs" is a Leading private equity firm dedicated to energy transition and innovation.

Investment focus

Software, Biotechnology, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.

Baekeland Funds is a seed capital fund formed to invest in companies developed at the University of Ghent.

Investment focus

Biotechnology, Hardware, Software
Funding Round, Series B, Series C
Belgium

Portfolio highlights

Caliopa — Caliopa NV develops and markets silicon photonics based optical transceivers for the data and telecommunications markets. The company was incorporated in 2010 and is based in Zwijnaarde, Belgium.
Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Trinean — Unchained Labs helps biologics & gene therapy researchers break free from tools that don't cut it. Crank up your research with our problem-solving products.

KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Series A, Series B
Belgium, United States, Luxembourg

Portfolio highlights

ELIS — Elis is a multi-services group in Europe and Brazil, specialized in the rental and maintenance of professional clothing and textile articles, as well as hygiene appliance and well-being services. With more than 19,000 employees spread across 13 countries, Elis consolidated turnover in 2014 was €1.331 billion and consolidated EBITDA reached €429million. Benefiting from more than a century of experience, Elis today services more than 240 000 businesses of all sizes in the hotel, catering, healthcare, industry, retail and services sectors, thanks to its network of nearly 300 production and distribution centers and 13 clean rooms, which guarantees it an unrivalled proximity to its clients.
Setle — During the renovation process, Settle assists in helping to make better judgments. Settle's goal is to increase renovation transparency. From increasing the energy efficiency of your home to getting the most out of your housing budget.
MICLEDI Microdisplays — MICLEDI Microdisplays is an experienced executive in the semiconductor industry,

Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.

Investment focus

Health Care, Biotechnology, Medical
Series A, Funding Round
Belgium

Portfolio highlights

Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.

Shaping new life-science ventures.

Investment focus

Biotechnology, Therapeutics, Health Care
Funding Round, Series A, Seed
The Netherlands, United States, United Kingdom

Portfolio highlights

Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Tanai Therapeutics — Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.
Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.

Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Belgium, United States, Spain

Portfolio highlights

Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.

Investment focus

Health Care, Manufacturing, Biotechnology
Series A, Seed, Funding Round
Belgium, France, United Kingdom

Portfolio highlights

BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
Octave — A sustainable, cost-effective and reliable energy storage system with second-life batteries from electric vehicles.

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Investment focus

Biotechnology, Medical, Therapeutics
Series A, Series B, Series C
United States, Belgium, The Netherlands

Portfolio highlights

Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies

Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.

Investment focus

Health Care, Biotechnology, AgTech
Seed, Series B, Funding Round
Belgium

Portfolio highlights

moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.

Investment focus

Health Care, Life Science, Medical
Funding Round, Seed, Series A
Belgium, Canada, France

Portfolio highlights

DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
HypnoVR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.

UCB Ventures is a €150 million strategic corporate venture fund

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Belgium, Spain

Portfolio highlights

ViaNautis — Precision Solutions
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).

New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series D
United States, United Kingdom, Belgium

Portfolio highlights

Glydways — A revolution in better mobility and public transportation.
Vuv Analytics — VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUVreflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Astraveus — Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies.
Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

AgroSavfe nv, a Belgium-based agro-biotech company

Investment focus

Biotechnology, Chemical, Veterinary
Series B, Series A, Seed
Belgium

Portfolio highlights

Animab — Animal Health Company
Virovet — Antiviral drugs and thermostable vaccines for livestock
Aphea.Bio — . .sustainableagriculture-section {. backgroundcolor: fff;. boxshadow: 0 0.40rem 0.40rem rgba(0, 0, 0, 0.25);. display: flex;. flexdirection: column;. overflow: hidden;. backgroundsize: cover;. }.. .herobanner {. display: flex;. flexdirection: column;. position: relative

Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Series A, Seed
The Netherlands, Belgium, United States

Portfolio highlights

Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

Vinnof is a venture capital firm that offers seed capital to innovative, early-stage startups based in Flanders, Belgium.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
Belgium, United Kingdom

Portfolio highlights

Apitope — Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of productcandidates developed with its proprietary platform technology.
Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Okapi Sciences — Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

AvenCell — Next generation immunotherapies for hard-to-treat cancers that are allogeneic and switchable.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Booster Therapeutics — Booster Therapeutics is a biotech business that regulates cellular homeostasis and develops treatments for age-related disorders.

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series B, Series A
Belgium, United States, France

Portfolio highlights

Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
PictorLabs — PictorLabs is a digital pathology company advancing AI-powered virtual staining technology to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence and health-tech product development, the Company is reimagining the ageold practice of histopathology. From a single unstained tissue sample, PictorLabs’ proprietary platform can sustainably produce an unlimited number of virtual stains that are indistinguishable from analogous chemical ones. PictorLabs' technology can replicate standard of care stains and perform specialized virtual biomarker stains for indications that require novel and accelerated diagnostic tests. To learn more, visit https://pictorlabs.ai/ and please follow PictorLabs on LinkedIn.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
Belgium, India

Portfolio highlights

AstriVax — AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
Medikabazaar — Medikabazaar is an online B2B marketspace for medical supplies and equipment. They are a single point of contact for all product-based needs, enabling medical institutions and individual practitioners alike to cut down on operational costs and making the best global brands available locally, all aided with the miracle that goes by the name oftechnology. They are connected with more than 50,000 medical establishments, 1,50,000 Independent Practitioners, and have partnered with 13,000+ suppliers all over India including ones in Tier 2, Tier 3 cities, and remoter locations to establish a strong foothold in India and simultaneously earn the respect of our clients. With the power of technology, we organized a haywire market in a country with perhaps the largest and most complex geographical structure in the world for this purpose. Our last-mile delivery system and 26 strategically placed Fulfilment Centres across India enable us to deliver essential medical supplies to healthcare facilities and help them nurture quality and timely patient care. With our first international office in the Middle East, we are transcending boundaries to deliver care, everywhere.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.

Investment focus

Biotechnology, Hardware, Software
Funding Round, Series B, Series C
Belgium, France, The Netherlands

Portfolio highlights

Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
Finquest — Tap into the largest private company database in the world to change the way you find and connect with M&A targets using Data, AI, & People.
Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.

Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences

Investment focus

Health Care, Manufacturing, Information Technology
Funding Round, Seed, Series A
Belgium, France, Luxembourg

Portfolio highlights

Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
SENSE in — SENSE in manufactures monitoring solutions based on thermomechanical sensors sensitive to deformation, pressure, temperature, humidity, and more. Their solutions evaluate in real time or periodically the expected characteristics and alert on abnormal behavior, threshold overruns, and damage.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Spectrawave — Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.
ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Orasis Pharmaceuticals — Discover how Orasis Pharmaceuticals is reshaping vision possibilities with innovative treatments for presbyopia.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
Ireland, United States, France

Portfolio highlights

MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
Mainstay Medical — Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.
Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company isbased in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

We empower high-potential entrepreneurship and democratize venture capital. Discover promising start-ups & SMEs and invest alongside business angels.

Investment focus

Health Care, Information Technology, Food and Beverage
Series A, Seed, Series B
Belgium, France

Portfolio highlights

Opinum — What is Opinum Data Hub? Our Data Hub is a secured Cloud-based platform that allows energy and environmental actors to centralise, enhance, analyse, and share data.
Digiteal — Digiteal offers a wide range of services for e-invoice presentment, electronic payments and open banking.
NietsCo — NietsCo. is the home of Botaniets Gin 0.0%, a leading selection of alcohol-free products, carefully distributed to the world's best restaurants, concept stores, shops and consumers.

Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.

Investment focus

Biotechnology, iOS, Construction
Series A, Seed, Funding Round
Belgium, United States

Portfolio highlights

CluePoints — CluePoints' Risk-Based Quality Management (RBQM) Software illuminates risks that could compromise patient safety, and enables compliance with ICH E6 (R2).
A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.

Leading venture capital fund with exclusive focus on micro/nano-electronics and advanced materials

Investment focus

Software, Manufacturing, Semiconductor
Series B, Series A, Funding Round
Belgium, United States, Germany

Portfolio highlights

Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
Silicon Line — Munich, Germany-based Silicon Line (www.silicon-line.com) is the unchallenged world leader in developing and providing innovative ultra-low-power optical link technology that enables the use of thin, long, lightweight and very high speed ‘active’ optical cables for a wide array of consumer electronics products – including TVs, set-top boxes, videogame consoles, augmented reality (AR) and virtual reality (VR) headsets and related devices – as well as commercial and industrial applications. ‘Active’ refers to powered electronics integrated within the cable.Clear evidence of Silicon Line’s global leadership in ultra-lower-power optical technology can be seen not only by its steadily evolving line of leading-edge and industry-first products – with more than 25 different products now in use – but also in its pivotal role within the HDMI Forum, where it has successfully led efforts to enhance support for active optical cable technology standards in the latest specification, HDMI 2.1.Founded in 2005 as an outsource integrated circuit (IC) design house, Silicon Line quickly developed proven expertise in ultra-low-power, analog and mixed-signal chip design. Billions of ICs based on its designs have been used in products of major brand-name manufacturers.
Silicon Mobility — Our solution enables carmakers to improve EV and HEV energy efficiency, increase range and accelerate charging time while reducing cost.

Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term. Our investment team, based in Europe and North America, brings its expertise andinternational network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Series C, Series B
France, United States, Belgium

Portfolio highlights

SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Software
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, Ireland

Portfolio highlights

ROCSYS — Meet the world's first autonomous charging solution for electrical vehicles in public transportation, logistics, material handling, and passenger cars.
Trucksters — We are a transportation company that focuses on providing long distance FTL trucking service through an innovative relay system based on artificial intelligence. We achieve transit times similar to air transport while reducing the costs of traditional road transportation.
Masdar Capital — Masdar Capital is developing & deploying commercial-scale renewable energy projects.

The Fund was established in 1994 to provide investment support for emerging biotech companies in the region and over its first 10 years invested some 36.3 million euro in businesses that ranged from Plant Genetic Systems, Innogenetics, Devgen and, most recently, Galapagos, a new listing on the stock exchange.Biotech Fund Flanders, whoseportfolio and investment policy were managed by the Governmentâ€:tm:s investment agency GIMV, was due to close investment activities after 10 years and perform only follow-up tasks until 2009. The Minister for the Economy, Fientje Moerman, has announced, however, that it will continue to operate until 2010.No additional money will be made available â€“ the Fund has some 12 million euro of its own resources from sales of previously held shares and is to recycle this and other returns. Its current portfolio includes investments valued at 19.7 million euro in six companies

Investment focus

Biotechnology, Pharmaceutical, Biopharma
Series B, Series C, Series D
Belgium, Togo, France

Portfolio highlights

Pronota — Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base ofinvestors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
Virovet — Antiviral drugs and thermostable vaccines for livestock
ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.

Investors by industry